Wednesday, September 03, 2025 8:07:55 PM
Maverick, I know you are a person who always adds a "different-strokes" way of strategically viewing things. So I am comforted in knowing we share a confidence in Maestro (LP) and that she has a plan to deploy against the dark forces at hand.
Absolutely, just like the pulling-rabbit-out-of-hats and plans she did over the years to bring the DCVax-L global Phase 3 clinical trial to a rich success and to build/finance this entire DCVax platform. That includes all the acquisitions, discoveries, patent families/IP, and state-of-the-art Sawston mfg facility. That is despite, and in the face of, broad market manipulation forces working against them, all while being R&D / non-revenue.
The shorts massively failed in the #1 thing they were supposed to do, take down the company.
Now DCVax is approaching the runway. And I think during take-off, we will have a better view and see the path will be littered with the losses from short positions, large synthetic short contracts, short hedge funds, and their counter party market makers.
Best to all longs and to you.
Absolutely, just like the pulling-rabbit-out-of-hats and plans she did over the years to bring the DCVax-L global Phase 3 clinical trial to a rich success and to build/finance this entire DCVax platform. That includes all the acquisitions, discoveries, patent families/IP, and state-of-the-art Sawston mfg facility. That is despite, and in the face of, broad market manipulation forces working against them, all while being R&D / non-revenue.
The shorts massively failed in the #1 thing they were supposed to do, take down the company.
Now DCVax is approaching the runway. And I think during take-off, we will have a better view and see the path will be littered with the losses from short positions, large synthetic short contracts, short hedge funds, and their counter party market makers.
Best to all longs and to you.
Sharing thoughts and opinions. To participate in group due diligence. Motto: Do not be a gullible FUDdable investor.
Recent NWBO News
- Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses • PR Newswire (US) • 07/08/2026 06:42:00 PM
- Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses • PR Newswire (US) • 07/08/2026 06:24:00 PM
- Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting • PR Newswire (US) • 07/02/2026 06:41:00 PM
- Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting • PR Newswire (US) • 07/02/2026 06:17:00 PM
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
